A first-in-human (FIH) Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of single ascending doses of ABBV-0805
Latest Information Update: 28 Oct 2021
At a glance
- Drugs ABBV 0805 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- 28 Oct 2021 New trial record
- 22 Sep 2021 Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders